Ivacaftor
Glucose Intolerance or Newly Diagnosis Diabetes
University Hospital, Strasbourg, FranceSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Glucose Intolerance or Newly Diagnosis Diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lumacaftor University Hospital, Strasbourg, France | D |
Same molecule, other indications
Ivacaftor is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →